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responses to linagliptin and identify relevant predictors of glycated hemoglobin (HbA1c) reduc-
tion in patients with type 2 diabetes mellitus (T2DM).
Methods and results: Data were pooled from three 24-week, placebo-controlled trials of similar
design (linagliptin, nZ 1651; placebo, nZ 607). Patients were categorized according to baseline
characteristics: age, T2DM duration, gender, body mass index (BMI), Homeostasis Model Assess-
ment of Insulin Resistance (HOMA-IR), and metabolic syndrome (MetS). Changes from baseline
in HbA1c after 24 weeks were assessed with analysis of covariance (ANCOVA). The proportion of
patients with baseline HbA1c >7% achieving HbA1c of 7% at week 24 were evaluated. Indepen-
dent predictors of HbA1c response with linagliptin were analyzed in a multivariate analysis with
ANCOVA. Linagliptin treatment led to signiﬁcant mean (SE) placebo-corrected reductions from
baseline in HbA1c across all subgroups (0.42% [0.11] to 0.79% [0.08]; all p < 0.001). Within
subgroups, HbA1c reduction was more pronounced in patients without MetS (0.74% [0.06];
treatment interaction p Z 0.0489). The proportion of patients with baseline HbA1c >7%
achieving a target HbA1c 7% was greater with linagliptin versus placebo (30.2% vs 11.5%; odds
ratio 3.82; 95% CI 2.82 to 5.17; p < 0.001). Characteristics signiﬁcantly predicting HbA1c reduc-
tions after 24 weeks were fasting plasma glucose and race (both p < 0.05).
Conclusion: This post-hoc analysis supports that linagliptin achieved clinically meaningful im-
provements in hyperglycemia in patients with diverse clinical characteristics. These improve-
ments were more pronounced in patients without MetS.
ª 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).OVA, analysis of covariance; BMI, body mass index; DPP-4, dipeptidyl peptidase-4; FAS, full analysis
A1c, glycated hemoglobin; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; IDF,
etS, metabolic syndrome; OR, odds ratio; T2DM, type 2 diabetes mellitus.
rs: NCT00621140, NCT00601250, NCT00602472.
f Endocrinology and Metabolism, Section of Metabolic Diseases, University of Pisa, Via Paradisa 2, 56124 Pisa,
50 541 521.
d.unipi.it (S. Del Prato).
time of the studies and manuscript development; currently employed by Daiichi Sankyo, Inc.
time of the studies and manuscript development.
etology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of
versity. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
Efﬁcacy and safety of linagliptin according to patient baseline characteristics 887Introduction
Recent diabetes guidelines emphasize the need for treat-
ment individualization, and advocate selection of phar-
macologic treatment for type 2 diabetes mellitus (T2DM)
based on multiple parameters (e.g. efﬁcacy, side effects,
impact on body weight, and cost) [1]. In this context,
prediction of response to a given treatment would be quite
useful. However, the current literature does not provide
clear, consistent insights regarding which non-genetic
patient characteristics might inﬂuence response to treat-
ment for T2DM [2,3]. Therefore, patients and health care
providers likely would beneﬁt if future clinical trials were
to designate patient subgroups prospectively for analyses
of efﬁcacy and safety in order to further improve individ-
ualized treatment concepts in T2DM. Dipeptidyl
peptidase-4 (DPP-4) inhibitors are of continuing interest in
T2DM, with recent data demonstrating the efﬁcacy of
these agents in more challenging patient groups such as
the elderly [4e7] and those with renal impairment [8].
The phase 3 clinical trial program of the DPP-4 inhibitor
linagliptin included predeﬁned characterizations of safety
and efﬁcacy data according to a broad range of patient
attributes. The use of linagliptin as monotherapy or add-on
combination therapy has been evaluated in three 24-week,
placebo-controlled, phase 3 trials of >2000 patients with
T2DM and results have been previously reported [9e11].
However, these 3 individual studies of linagliptin were not
sufﬁcient for determining whether some patient charac-
teristics may affect clinical outcomes associated with
linagliptin therapy. These trials had similar designs, with
identical study duration, primary endpoint deﬁnition, and
safety assessments, which allowed data to be pooled in an
attempt to more efﬁciently explore potential factors pre-
dicting therapeutic response. Thus, pooled safety and ef-
ﬁcacy data from these 3 trials were analyzed across
predeﬁned subgroups to explore to what extent baseline
characteristics could be associated with variances in
glucose-lowering treatment response or increased risk of
side effects.
Methods
Study population
This retrospective analysis pooled data from individuals
with T2DM from these 3 previously reported trials evalu-
ating the safety and efﬁcacy of linagliptin 5 mg once daily
given as monotherapy (NCT00621140) [9], as add-on
therapy in patients with T2DM inadequately controlled
with metformin (NCT00601250) [11], and as add-on ther-
apy in patients with T2DM inadequately controlled with
metformin plus a sulfonylurea (NCT00602472;
Supplementary Table S1) [10]. Patients were randomized
to linagliptin and placebo in ratios of 2:1 (NCT00621140)
[9] and 3:1 (NCT00601250, NCT00602472) [10,11]. Studies
were carried out according to the Declaration of Helsinki
and International Conference on Harmonisation good
clinical practice principles (October 1996) and nationalgood clinical practice regulations where applicable. The
protocols, informed consent, and patient information
forms were reviewed and approved by the local institu-
tional review boards.
Efﬁcacy and safety analysis
For this pooled analysis, patients were grouped into pre-
deﬁned baseline categories according to age (50, 51 to
<65, 65 to <75, 75 years), gender (male, female), dura-
tion of T2DM based on time elapsed since documented
diagnosis (1, >1 to 5, >5 years), body mass index (BMI;
<25, 25 to <30 [overweight], 30 [obese] kg/m2), and the
following 2 additional categories. Insulin-resistance cate-
gories were deﬁned according to prespeciﬁed values of
Homeostasis Model Assessment of Insulin Resistance
(HOMA-IR): 4.0, >4.0 to 5.5, >5.5 to 8.5, and >8.5.
Metabolic syndrome (MetS) was determined according to
the International Diabetes Federation (IDF) criteria [12].
Efﬁcacy analyses were performed on the full analysis
set (FAS), which consisted of all randomized participants
who were treated with 1 dose of study medication, who
had a baseline glycated hemoglobin (HbA1c) measurement
and 1 on-treatment HbA1c measurement. Efﬁcacy mea-
surements after start of rescue therapy were replaced by
missing values. Missing data were imputed using a last
observation carried forward approach.
The change from baseline in HbA1c after 24 weeks was
compared between the linagliptin and placebo groups
using analysis of covariance (ANCOVA). The general model
included continuous baseline HbA1c, washout, treatment,
study, subgroup, and treatment by subgroup interaction.
All subgroup analyses were performed at a signiﬁcance
level of 5%.
The proportion of FAS patients with a baseline HbA1c
>7% achieving a target HbA1c 7% at week 24 was eval-
uated overall. Logistic regression was used to model the
odds ratio (OR) for achieving HbA1c 7% with linagliptin
versus placebo treatment.
Additionally, the relationship between change from
baseline in HbA1c after 24 weeks and baseline variables of
interest (age, BMI, duration of T2DM, gender, fasting plasma
glucose [FPG], fasting plasma insulin, MetS) was analyzed
usingmultivariate analysis with ANCOVA. It should be noted
that baseline FPG and baseline fasting plasma insulin were
used in lieuofHOMA-IRandHOMA-%B. The2HOMA indexes
are different linear transformations of the same 2 variables
[13]: FPG and fasting plasma insulin, hence the 2 indexes
would be associated. The ﬁxed factors and covariates (study,
treatment, washout, and baseline HbA1c) were included in
all models as forced-in (core) variables independent of their
p value [14]. First, the core model plus each of the baseline
variables of interest were modeled separately. The values of
2 log likelihood were then obtained for each model and
compared to the null model (i.e. the core model) to deter-
mine if baseline variablesof interest reduced the value of this
statistic (2 log likelihood), based on the chi-squared dis-
tribution (p < 0.05). Second, the baseline variables deemed
to be importantweremodeled togetherwith the coremodel
Table 1 Patient demographics and baseline characteristics (FAS).
Linagliptin
(n Z 1624)
Placebo
(n Z 600)
Age (years) 57.4 (10.0) 56.5 (10.2)
Male (%) 49.2 50.5
Race (%)
White 57.6 57.2
Asian 41.7 42.1
Black 0.7 0.7
BMI (kg/m2) 29.0 (4.9) 29.0 (4.8)
BMI category (%)
<25 kg/m2 22.2 22.5
25 to <30 kg/m2 40.1 40.3
30 kg/m2 37.6 37.2
HbA1c (%) 8.1 (0.8) 8.1 (0.9)
Presence of MetS (%)a 63.3 62.3
Duration of T2DM (%)
1 year 12.2 14.3
1e5 years 30.0 31.2
>5 years 57.8 54.5
HOMA-IR, mean (SD)
(mU/L$mmol/L)b
4.7 (5.7) 4.4 (4.0)
HOMA-IR (%)b
4.0 mU/L$mmol/L 59.8 59.2
>4.0 to 5.5 mU/L$mmol/L 15.3 15.4
>5.5 to 8.5 mU/L$mmol/L 13.1 14.6
>8.5 mU/L$mmol/L 11.8 10.8
Fasting C-peptide (nmol/L)c 0.948 (0.481) 0.994 (0.529)
Previous OAD (%)
None 11.5 15.5
1 30.7 31.8
2 57.9 52.7
BMI: body mass index; FAS: full analysis set; HbA1c: glycated he-
moglobin; HOMA-IR: Homeostasis Model Assessment of Insulin
Resistance; MetS: metabolic syndrome; OAD: oral antidiabetes
drug; T2DM: type 2 diabetes mellitus.
Data are mean (SD) or % of patients.
a According to the International Diabetes Federation deﬁnition.
b Values are based on patients from the FAS with nonmissing
HOMA-IR values. Values were missing for 261 and 93 patients in the
linagliptin and placebo groups, respectively.
c Linagliptin n = 263, placebo = 106.
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likelihood was obtained. As variables can lose importance
when modeled with certain other variables, the change in
2 log likelihood was also obtained when each of the
important baseline variables of interest (in model 1) was
omitted. Only variables deemed important after this step
were retained (henceforth referred to as model 2). Third,
baseline variables of interest that were deemed not of in-
terest in theﬁrst stepmaybecome important in thepresence
of the variables inmodel 2. These variables were then added
separately tomodel 2 and the value of2 log likelihoodwas
obtained to see if the value of the statistic (2 log likelihood)
was reduced from model 2. Those baseline variables of in-
terest deemed of importance within this step were then
added tomodel2 (henceforth referred to asmodel3). Fourth,
a check was made to ascertain if any further terms could be
omitted from model 3.
Safety analyses were performed on the treated set,
which consisted of all patients treated with 1 dose of
study drug. Adverse events (AEs) were summarized using
descriptive statistics, without any formal statistical testing.
All AEs were coded using the Medical Dictionary for Reg-
ulatory Activities version 12.1.
Results
Patient population
In total, 2258 patients with T2DM (linagliptin, n Z 1651;
placebo, nZ 607) were randomized and received 1 dose
of study drug (treated set). The efﬁcacy population (FAS)
comprised 2224 patients (linagliptin, n Z 1624; placebo,
n Z 600). Baseline demographic and clinical characteris-
tics for the FAS were similar between the 2 treatment
groups (Table 1). Gender was evenly distributed. Overall,
58% of study participants were white and the remainder
predominantly Asian (42%). More than one-third (38%) of
participants were obese (mean BMI  SD, 29.0  4.8 kg/
m2). Most (63%) patients met the IDF criteria for MetS, 57%
had T2DM duration >5 years, and 10% had HOMA-IR
>8.5 mU/L$mmol/L. Mean fasting C-peptide levels were
comparable between the treatment groups, and more than
half of participants were taking 2 oral glucose-lowering
medications.
When baseline characteristics were stratiﬁed according
to age, duration of T2DM, BMI, HOMA-IR, presence of
MetS, or gender, notable differences were seen across
subgroups (Supplementary Tables S2e7). As expected, a
greater proportion of older patients had duration of dia-
betes >5 years and used 2 glucose-lowering drugs.
Additionally, most patients aged >50 years were white,
whereas most patients 50 years were Asian. Most pa-
tients with a duration of diabetes 1 year were Asian,
whereas those with a longer duration of diabetes were
more often white. Mean HOMA-IR values were lowest in
patients with duration of diabetes >5 years. Mean (SD)
fasting plasma insulin levels were lower in patients with
duration of diabetes >5 years (9.9  10.3 mU/L) than in
those with duration of diabetes <1 year (13.0  12.4 mU/L). These ﬁndings suggest that reduced mean HOMA-IR
values in patients with long-standing diabetes may be a
result of low residual b-cell function. Among the BMI
subgroups, the mean value for HOMA-IR and the propor-
tion of white patients were higher in the BMI 30 kg/m2
subgroup than in the BMI <25 kg/m2 subgroup. In the
MetS subgroups, a greater percentage of patients without
MetS had mean HOMA-IR of 4.0 mU/L$mmol/L, were
Asian, and had lower BMI. In the gender subgroups, a
greater proportion of females than males had MetS and
used 2 glucose-lowering drugs.
Efﬁcacy
In the pooled analysis of efﬁcacy, linagliptin showed sig-
niﬁcant (p  0.0013) mean placebo-adjusted reductions in
HbA1c levels across all subgroups studied (Fig. 1). Mean
(SE) placebo-corrected reductions from baseline in
HbA1c ranged from 0.42% (0.11) to 0.79% (0.08)
across all subgroups. The effect of linagliptin was similar
−1.5 −1.0 −0.5 0.0
Yes
No
>8.5
>5.5 to ≤8.5
>4.0 to ≤5.5
≤4.0
≥30
25 to <30
<25
 Male
 Female
>5
>1 to ≤5
≤1
≥75
65 to <75
51 to <65
≤50
Placebo-adjusted mean difference in % HbA1c (95% CI; [p value])
Age (years)
Gender
Duration of T2DM (years)
BMI (kg/m )
HOMA-IR (mU/L•mmol/L)
Presence of MetS
–0.59 (–0.74, –0.43; [<0.0001])
–0.68 (–0.78, –0.57; [<0.0001])
–0.60 (–0.77, –0.43; [<0.0001])
–0.77 (–1.24, –0.30; [0.0013])
Interaction p = 0.6955
Interaction p = 0.4147
Interaction p = 0.6113
Interaction p = 0.1026
Interaction p = 0.3025
Interaction p = 0.0489
−0.54 (−0.75, −0.33; [<0.0001])
−0.61 (−0.75, −0.47; [<0.0001])
−0.68 (−0.79, −0.58; [<0.0001])
−0.66 (−0.77, −0.55; [<0.0001])
−0.62 (−0.73, −0.51; [<0.0001])
−0.79 (−0.96, −0.63; [<0.0001])
−0.57 (−0.69, −0.45; [<0.0001])
−0.63 (−0.76, −0.50; [<0.0001])
−0.65 (−0.76, −0.54; [<0.0001])
−0.69 (−0.91, −0.47; [<0.0001])
−0.42 (−0.65, −0.20; [0.0002])
−0.64 (−0.89, −0.38; [<0.0001])
−0.74 (−0.87, −0.62; [<0.0001])
−0.58 (−0.68, −0.48; [<0.0001])
Characteristic
Linagliptin superior
to placebo
No change
versus placebo
Figure 1 Placebo-corrected adjusted mean HbA1c (%) reduction from baseline after 24 weeks by subgroup (full analysis set [last observation carried
forward]). BMI: body mass index; CI: conﬁdence interval; HbA1c: glycated hemoglobin; HOMA-IR: Homeostasis Model Assessment of Insulin
Resistance; MetS: metabolic syndrome; T2DM: type 2 diabetes mellitus.
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T2DM, BMI, and HOMA-IR (treatment interaction, p > 0.1).
Within the BMI subgroup, the treatment difference
measured by mean change in HbA1c favored linagliptin in
all subcategories; however, the magnitude of effect was
greatest, though not statistically signiﬁcant, for patients
with BMI <25 kg/m2 (treatment interaction, p Z 0.1026).
Similarly, when data were stratiﬁed based on presence or
absence of MetS, linagliptin was superior to placebo in
reducing mean HbA1c in both strata; however, the effect of
linagliptin was greater in patients without MetS (treat-
ment interaction, pZ 0.0489). These subgroups included a
higher percentage of Asian patients than those of other
races; in patients with BMI <25 kg/m2, 80% were Asian
(Supplementary Table S4) and in patients without MetS,
53% were Asian (Supplementary Table S6).
In addition, more patients with baseline HbA1c >7%
treated with linagliptin (30.2% [n/N Z 450/1491]) ach-
ieved an HbA1c 7% versus those treated with placebo
(11.5% [n/N Z 62/538]; OR 3.82; 95% CI 2.82 to 5.17;
p < 0.0001).Clinical predictors of HbA1c reduction after 24 weeks
Selected baseline variables (age, BMI, gender, duration of
T2DM, continuous FPG, continuous fasting plasma insulin,
MetS) were modeled in an ANCOVA along with the forced-
in (i.e. core) variables known to affect treatment response
(treatment, study, washout, continuous baseline HbA1c)
using the statistical approach outlined earlier to assess the
potential predictive determinants of change from baselinein HbA1c after 24 weeks. After applying this method, 2
clinical parameters were kept in the ﬁnal model; baseline
FPG and race (in addition to the core variables).Safety
Table 2 summarizes AE data across the subgroups. The
incidence of overall AEs, AEs leading to discontinuation, or
serious AEs was similar in patients who received lina-
gliptin versus placebo when analyzed according to BMI,
T2DM duration, HOMA-IR, MetS, gender, and age (except
75 years). Among those aged 75 years, the overall
incidence of AEs was numerically higher with placebo than
with linagliptin (93% [n/NZ 14/15] vs 70% [n/NZ 42/60]);
however, this subgroup was small. The incidence of serious
AEs ranged from 2.2 to 4.3% with linagliptin versus 2.2 to
6.7% for placebo for patients across all categories in all
subgroups.
The overall incidence of investigator-deﬁned hypogly-
cemia AEs was 11.6% for linagliptin versus 7.9% for placebo.
However, the incidence was <1% in linagliptin-treated
patients in the monotherapy (NCT00621140) and add-on
to metformin (NCT00601250) studies, whereas an
increased frequency of hypoglycemia with linagliptin only
occurred in those with a background of sulfonylurea
(NCT00602472; 23.7%, linagliptin vs 16.0%, placebo). The
incidence of conﬁrmed hypoglycemia AEs across subgroup
categories ranged from 0.5 to 26.7% for linagliptin versus
rates of 0 to 20% for placebo. In the overall pooled analysis,
incidence of conﬁrmed hypoglycemia AEs (investigator-
deﬁned hypoglycemia AEs conﬁrmed with plasma
Table 2 Adverse events in patients by selected baseline subgroups (TS).
Characteristic (n Z linagliptin/placebo) Any AE (%) AEs leading to discontinuation (%) Serious AEs (%)
Linagliptin Placebo Linagliptin Placebo Linagliptin Placebo
Age
50 years (n Z 398/164) 55.0 54.3 1.5 1.8 2.5 3.7
51 to <65 years (n Z 845/304) 58.3 58.2 1.9 1.6 3.1 2.6
65 to <75 years (n Z 348/124) 64.1 58.9 2.9 3.2 4.3 4.8
75 years (n Z 60/15) 70.0 93.3 5.0 0 3.3 6.7
Time since diagnosis
1 years (n Z 203/89) 48.3 51.7 2.5 2.2 3.0 3.4
1e5 years (n Z 495/188) 56.4 58.5 2.4 1.6 2.8 3.7
>5 years (n Z 953/330) 65.3 62.7 2.3 2.7 3.5 4.2
Gender (%)
Male (n Z 813/307) 56.0 59.6 1.7 2.0 3.0 3.3
Female (n Z 838/300) 62.3 56.7 2.5 2.0 3.5 3.7
BMI
<25 kg/m2 (n Z 366/136) 58.2 64.7 1.9 4.4 4.1 5.1
25 to <30 kg/m2 (n Z 662/248) 58.0 54.8 2.6 1.2 3.0 3.6
30 kg/m2 (n Z 623/223) 61.0 57.8 1.8 1.3 2.9 2.2
HOMA-IR (mU/L$mmol/L)a
4.0 (n Z 828/304) 60.5 61.5 1.9 1.6 3.9 3.9
>4.0 to 5.5 (n Z 214/79) 61.2 62.0 4.7 1.3 2.3 3.8
>5.5 to 8.5 (n Z 181/74) 61.9 56.8 1.7 1.4 2.2 5.4
>8.5 (n Z 165/55) 60.0 58.2 1.8 5.5 3.0 5.5
Presence of MetS
No (n Z 603/230) 56.6 59.6 2.7 3.9 4.0 3.0
Yes (n Z 1047/377) 62.8 59.9 2.2 1.3 2.8 4.5
AE: adverse event; BMI: body mass index; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; MetS: metabolic syndrome;
TS: treated set.
a Does not include AEs for patients missing HOMA-IR.
890 S. Del Prato et al.glucose  70 mg/dL or where assistance was required) was
9.6% for linagliptin versus 6.4% for placebo. Very few
events occurred among patients with T2DM duration of
1 year (Table 3).Discussion
The demographics of the future population of patients
with T2DM will be characterized by a shift toward a higher
prevalence of obesity and associated risk constellations
alongside longer disease duration. As a result, patient
heterogeneity is expected to further increase, with higher
proportions of patients presenting with dyslipidemia, hy-
pertension, insulin resistance, declining b-cell function,
and overall diabetes-related complications. All of these
factors may inﬂuence individualized treatment choices
relating to achievement of glycemic targets [1].
The aim of this post-hoc analysis of three phase 3 trials
from the linagliptin program was to explore whether
treatment response and overall safety of the DPP-4 in-
hibitor linagliptin may vary based on clinically relevant
patient characteristics, such as age, disease duration,
obesity, insulin resistance, and prevalence of MetS. Lina-
gliptin therapy led to signiﬁcant improvements of hyper-
glycemia in all predeﬁned subgroups and was well
tolerated. Overall, the mean placebo-corrected HbA1c re-
ductions with linagliptin reported in this analysis (0.42
to 0.79%) were generally consistent with the placebo-
corrected reductions reported in the individual studypopulations in primary phase 3 studies, which were
mainly composed of patients on stable glucose-lowering
background treatment (0.62 to 0.69%) [9e11].
Improvements in HbA1c from baseline at week 24
favored linagliptin in all subgroups studied; however,
heterogeneous treatment response was observed in the
MetS category. Despite numerically small differences
among subgroups, linagliptin reduced HbA1c to a greater
extent in patients without versus with MetS, and showed a
trend for a greater reduction in patients with normal body
weight compared with those who were overweight or
obese. Although our analyses cannot provide evidence for
any underlying causality between the observed different
treatment responses in those subgroups, one likely
explanation may be the well-known close relationship
between features of peripheral tissue and liver insulin
resistance with other clinical parameters, such as presence
of MetS or increased BMI. The DPP-4 inhibitors predomi-
nantly increase glucose-dependent insulin secretion from
pancreatic b-cells and this mode of action may lead to
more pronounced treatment responses in conditions of
preserved peripheral tissue insulin sensitivity. Baseline
characteristics deemed signiﬁcant in the predictive anal-
ysis of HbA1c reduction after 24 weeks were FPG and race.
Differences in BMI across ethnic groups have been
shown to mediate the efﬁcacy of DPP-4 inhibitors ac-
cording to some studies [15e17]. For example, among
Korean T2DM subjects, those with low BMI were more
likely to respond to sitagliptin add-on therapy [16]. A
Table 3 Overall incidence of conﬁrmeda hypoglycemia adverse
events by selected baseline subgroups (TS).
Characteristica
(n Z linagliptin/placebo)
Linagliptin (%) Placebo (%)
Age
50 years (n Z 398/164) 7.0 3.7
51 to <65 years (n Z 845/304) 9.1 6.6
65 to <75 years (n Z 348/124) 10.9 8.1
75 (n Z 60/15) 26.7 20.0
Time since diagnosis
1 year (n Z 203/89) 0.5 0
>1 to 5 years (n Z 495/188) 6.9 5.3
>5 years (n Z 953/330) 13.0 8.8
Gender
Male (n Z 813/307) 8.4 6.2
Female (n Z 838/300) 10.9 6.7
BMI
<25 kg/m2 (n Z 366/136) 10.1 7.4
25 to <30 kg/m2 (n Z 662/248) 9.8 6.5
30 kg/m2 (n Z 623/223) 9.1 5.8
HOMA-IR (mU/L$mmol/L)b
4.0 (n Z 828/304) 12.2 8.6
>4.0 to 5.5 (n Z 214/79) 6.1 3.8
>5.5 to 8.5 (n Z 181/74) 6.1 5.4
>8.5 (n Z 165/55) 7.3 3.6
Presence of MetSc
No (n Z 603/230) 7.1 4.8
Yes (n Z 1047/377) 11.1 7.4
BMI: body mass index; HOMA-IR: Homeostasis Model Assessment
of Insulin Resistance; MetS: metabolic syndrome; TS: treated set.
a A conﬁrmed hypoglycemia adverse event is deﬁned as any
investigator-deﬁned hypoglycemia adverse event conﬁrmed with a
plasma glucose 70 mg/dL or where assistance is required.
b Does not include incidence of hypoglycemia for patients missing
HOMA-IR.
c According to the International Diabetes Federation deﬁnition.
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monotherapy or combination therapy showed greater
HbA1c-lowering efﬁcacy of DPP-4 inhibitor therapy in
Asian-dominant studies (>50% Asian participants)
compared with non-Asian dominant studies [15]. Howev-
er, the relationship between the percentage of Asian par-
ticipants and HbA1c-lowering efﬁcacy was no longer
signiﬁcant after adjusting for BMI. In a study of linagliptin
monotherapy in Asian patients, the effectiveness of lina-
gliptin versus placebo was not inﬂuenced by BMI [18]. In
the current post-hoc analysis, the imbalance in Asian pa-
tients across BMI subgroups may be contributing to the
differences in HbA1c reduction and contributing to the
signiﬁcant association between race and efﬁcacy of lina-
gliptin. Moreover, the interpretation of our results is
limited by the nature of this post-hoc analysis of studies of
short duration. The relationship between HbA1c-lowering
and other factors closely related to BMI, including insulin
sensitivity among different racial/ethnic groups, warrants
further evaluation.
Based on our exploratory predictive analyses, we also
conﬁrmed that baseline FPG, in combination with the core
model consisting of baseline HbA1c, was a signiﬁcant
predictor of linagliptin efﬁcacy. Our results are supported
by a recent meta-regression analysis of 98 randomizedcontrolled trials of DPP-4 inhibitors versus placebo or any
comparator drug with a follow-up duration longer than 12
weeks [19]. In their meta-analysis, baseline HbA1c and FPG
were predictive of HbA1c response to individual DPP-4
inhibitors; FPG improved the predictive value of HbA1c,
but alone FPG was not signiﬁcant. In a separate meta-
analysis, the placebo-corrected effect of DPP-4 inhibitors
on HbA1c was greater in patients with a lower baseline
FPG and HbA1c [20].
Our ﬁndings differ from those of other studies that have
investigated the relationship between age and HbA1c
response to DPP-4 inhibition. Although other studies have
shown greater efﬁcacy of DPP-4 inhibitors among older
patients versus younger patients [20], age was not found
to be a signiﬁcant predictor of linagliptin efﬁcacy in this
pooled analysis. A wider range of placebo-adjusted mean
changes in HbA1c among those aged 75 years was likely
due to small subgroup size compared with the sample size
of the other age subgroups. In a separate study of patients
70 years of age, linagliptin treatment for 24 weeks
signiﬁcantly lowered HbA1c [4].
In our analysis, the rates of serious AEs and AEs leading
to discontinuation were comparable for linagliptin versus
placebo across all patient subgroups. Linagliptin retained
an acceptable safety proﬁle across all different categories,
which supports it as a treatment option for a broad range
of patients with T2DM. The rates of hypoglycemia and
other AEs in patients treated with linagliptin were gener-
ally comparable with placebo when assessed within sub-
groups. Therefore, these ﬁndings are consistent with the
recent results of 2 studies evaluating long-term therapy
with linagliptin, demonstrating favorable safety and efﬁ-
cacy through 2 years of treatment with linagliptin [21,22].
Linagliptin was well tolerated with no particular clinical
patient parameter predicting an increased risk for devel-
oping AEs, including hypoglycemia.
In summary, this post-hoc analysis in predeﬁned sub-
groups from three phase 3 studies showed that no MetS,
Asian ethnicity, and baseline FPG inﬂuenced the pharma-
cologic response to linagliptin. Leaner individuals
appeared to have relatively greater reductions in HbA1c,
whereas heavier individuals and those with MetS experi-
enced a still meaningful but numerically slightly lower
response. This ﬁnding could suggest that a leaner patient
who may be more insulin deﬁcient than insulin resistant,
as it is believed to be the case for most Asian patients with
diabetes, has a better response to an insulin secretagogue
than a patient with a higher BMI and greater insulin
resistance. However, the association between BMI and ef-
ﬁcacy may be confounded by race/ethnicity, thus conclu-
sions about this potential effect cannot be drawn.
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